Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
Recruiting · NCT04906096 · Registry updated 2026-08-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL | primary central nervous system lymphoma | Recruiting | Phase 2 | 2026-08-05 | NCT04906096 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Kazia Therapeutics Limited | 5 |
| Lakshmi Nayak, MD | 1 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Brigham and Women's Hospital | Boston | United States | 511 |
| Dana Farber Cancer Institute | Boston | United States | 133 |